



Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

December 6, 2023

DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) -- [Bioventus Inc.](#) (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to [DUROLANE](#) to treat knee osteoarthritis (OA) pain. **DUROLANE**, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. **DUROLANE** will be one of two single-injection HA products under contract.

OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as **DUROLANE**, help manage knee OA pain.

"We are pleased **DUROLANE** is among the preferred options available to both Aetna™ Medicare Advantage members and physicians," said Anthony Doyle, General Manager, Pain Treatments and Restorative Therapies for Bioventus. "Both now have access to a safe HA product that is proven to provide relief from knee OA pain."

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on [LinkedIn](#) and [Twitter](#). Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:

Dave Crawford

919-474-6787

dave.crawford@bioventus.com